Choice A rationale

Montelukast does not increase the production of mucus in the lungs. In fact, it helps to reduce inflammation and may be used to prevent asthma attacks.

Choice B rationale

Montelukast is a leukotriene modifier that helps to reduce inflammation and prevent asthma attacks and exercise-induced bronchoconstriction. It works by blocking the action of leukotriene D4 in the lungs resulting in decreased inflammation and relaxation of smooth muscle. This prophylactic limitation of the inflammatory response to allergens is a key function of montelukast.

Choice C rationale

Montelukast does not contract the smooth muscles located in the respiratory tract. Instead, it helps to relax the smooth muscles in the lungs, reducing inflammation and making it easier to breathe.

Choice D rationale

Montelukast does not directly repair damaged tissue in the base of the lungs. Its primary function is to prevent and manage symptoms of asthma and allergies by reducing inflammation in the airways.

Choice A rationale
Heart rate is an important vital sign to monitor in patients, but it is not the primary outcome
data to prioritize when administering a 20% mannitol intravenous (IV) solution. Mannitol is a diuretic that works by increasing the amount of urine produced. Therefore, while heart rate can be affected by fluid balance changes, it is not the most directly relevant outcome to monitor in this context.
Choice B rationale
Ankle circumference could be an indicator of peripheral edema, which might suggest fluid
overload or poor kidney function. However, in the context of mannitol administration, which is a diuretic and would be expected to decrease fluid overload, ankle circumference is not the primary outcome to monitor.
Choice C rationale
Urinary output is the correct answer. Mannitol is an osmotic diuretic that increases urine
production. It is used to reduce intracranial and intraocular pressure by drawing water out of tissues and into the bloodstream, from where it can be excreted by the kidneys. Therefore, urinary output is the most direct measure of its effectiveness and is the key outcome that should be monitored.
Choice D rationale
Dietary intake is always important to monitor in patients, especially those receiving IV
therapy, as it can impact electrolyte balance and overall health status. However, it is not the primary outcome to monitor when administering mannitol.